-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Initiates Coverage On Intellia Therapeutics with Underweight Rating, Announces Price Target of $8

Benzinga·10/06/2026 12:11:03
Barclays analyst Gena Wang initiates coverage on Intellia Therapeutics (NASDAQ:NTLA) with a Underweight rating and announces Price Target of $8.